<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FAMOTIDINE</span><br/>(fa-moe'ti-deen)<br/><span class="topboxtradename">Pepcid, </span><span class="topboxtradename">Pepcid AC<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antisecretory agent (h<sub>2</sub>-receptor antagonist)</span><br/><b>Prototype: </b>Cimetidine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg, 40 mg tablets; 40 mg/5 mL suspension; 10 mg/mL, 20 mg/50 mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Thiazole derivative, structurally similar to histamine and pharmacologically similar to cimetidine. A potent competitive inhibitor
         of histamine at histamine (H<sub>2</sub>) receptor sites in gastric parietal cells. Inhibits basal, nocturnal, meal-stimulated, and pentagastrin-stimulated gastric
         secretion; also inhibits pepsin secretion. Is 20160 times more potent than cimetidine and 320 times more potent
         than ranitidine. Does not affect gastric emptying or exocrine pancreatic function.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces parietal cell output of hydrochloric acid; thus, detrimental effects of acid on gastric mucosa are diminished.</p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term treatment of active duodenal ulcer. Maintenance therapy for duodenal ulcer patients on reduced dosage after healing
         of an active ulcer. Treatment of pathologic hypersecretory conditions (e.g., Zollinger-Ellison syndrome), benign gastric ulcer,
         gastroesophageal reflux disease (GERD), gastritis.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Stress ulcer prophylaxis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safe use during pregnancy (category B), by nursing mothers.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal insufficiency.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Duodenal Ulcer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 40 mg h.s. or 20 mg b.i.d. <span class="rdroute">PO Maintenance Therapy</span> 20 mg h.s. <span class="rdroute">IV</span> 20 mg q12h<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span> 0.5 mg/kg q812h (max: 40 mg/d)<br/><br/><span class="indicationtitle">Pathological Hypersecretory Conditions</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20160 mg q6h<br/><br/><span class="indicationtitle">GERD, Gastritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg b.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 1 mg/kg/d in 2 divided doses (max: 40 mg b.i.d.)<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with liquid or food of patient's choice; an antacid may also be given if patient is also on antacid therapy.</li>
<li>Store at 15°30° C (59°86° F). Protect from moisture and strong light; do not freeze.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     					Note: Verify correct IV concentration and rate of infusion/injection with physician before administration to infants or children.
                     				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute 20 mg (2 mL) famotidine IV solution (containing 10 mg/mL) with D5W, NS, or other compatible IV diluent (see manufacturer's
                  directions) to a total volume of 5 or 10 mL.  <span class="methodtype">IV Infusion:</span> Dilute 2 mL famotidine IV with 100 mL compatible IV solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over not less than 2 min.  <span class="methodtype">IV Infusion:</span> Infuse over 1530 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span>
<b>Amphotericin B, azithromycin, cholesteryl complex</b>, <b>cefepime</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store IV solution at 2°8° C (36°46° F); reconstituted IV solution is stable for 48 h at room
            temperature 15°30° C (59°86° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, headache, confusion, depression. <span class="typehead">GI:</span> Constipation, diarrhea. <span class="typehead">Skin:</span> Rash, acne, pruritus, dry skin, flushing. <span class="typehead">Hematologic:</span> Thrombocytopenia. <span class="typehead">Urogenital:</span> Increases in BUN and serum creatinine. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Incompletely absorbed from GI tract (4050% reaches systemic circulation). <span class="typehead">Onset:</span> 1 h. <span class="typehead">Peak:</span> 13 h PO; 0.53 h IV. <span class="typehead">Duration:</span> 1012 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 2.54 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for improvement in GI distress.</li>
<li>Monitor for signs of GI bleeding.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that pain relief may not be experienced for several days after starting therapy.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>